On Dec. 3, 1984, the worst industrial accident in history unfolded in India. No punishment meted out has fit the immensity of the wrongdoing
With aviation fanatics keeping a close watch outside aircraft factories, little is secret
With Walmart workers promising their biggest strike, here's how to understand the action on Black Friday
How Anita Sarkeesian is trying to change the $25 billion video game industry
Subsidies from developers can lower interest rates to zero
Holiday gifts for every workstation in life, whether you're fetching coffee, announcing your IPO, or playing tennis all day
Graduate students get paid close to the minimum wage to do high-level coding work for tech companies
A look at how business owners profiled in Bloomberg Businessweek are coping with the latest unrest
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."